SCHEMBL23213206

SCHEMBL23213206

CC(C)(C)OC(=O)N1CC2(C[C@H](N3CCC(c4ccccc4C4=CCOCC4)CC3)CO2)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 9/20 0.51
CHRM1 P11229 9/20 0.51
CHRM2 P08172 3/20 0.38
PDK4 Q16654 1/20 0.35
IDO1 P14902 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
RORC P51449 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3R2 O00459 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
PIK3R5 Q8WYR1 1/20 0.32
PIK3R3 Q92569 1/20 0.32
CHRM5 P08912 1/20 0.32
NAMPT P43490 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29871295 0.97 CHRM4 (0.49) CHRM4CHRM1CHRM2PDK4IDO1
SCHEMBL29619686 0.92 CHRM4 (0.53) CHRM4CHRM1CHRM2PDK4IDO1
SCHEMBL29871235 0.91 CHRM4 (0.48) CHRM4CHRM1CHRM2PDK4RORC
SCHEMBL29619692 0.90 CHRM4 (0.54) CHRM4CHRM1CHRM2HRH3GPR119
SCHEMBL29871434 0.88 CHRM4 (0.49) CHRM4CHRM1CHRM2PDK4IDO1
SCHEMBL23213371 0.88 CHRM4 (0.52) CHRM4CHRM1CHRM2CHRM5
SCHEMBL23213373 0.88 CHRM4 (0.52) CHRM4CHRM1CHRM2CHRM5
SCHEMBL23209975 0.86 CHRM4 (0.49) CHRM4CHRM1CHRM2PDK4IDO1
SCHEMBL23209974 0.86 CHRM4 (0.49) CHRM4CHRM1CHRM2PDK4IDO1
SCHEMBL29691232 0.86 CHRM4 (0.49) CHRM4CHRM1CHRM2PDK4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119390705-A 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2025-02-07 CN disclosed
CN-114555606-B 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2024-10-01 CN disclosed
US-20240140959-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2024-05-02 US disclosed
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 US disclosed
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-12-29 US disclosed
US-11485742-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2022-11-01 US disclosed
CN-114555606-A 5-oxa-2-azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2022-05-27 CN disclosed
WO-2021070091-A1 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485742-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20240140959-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.